The Interleukin‐1 Receptor–Associated Kinase 4 Inhibitor PF‐06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial

Overview of attention for article published in Arthritis & Rheumatology, November 2021

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (70th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 4 X users

patent: 1 patent

Readers on

mendeley: 73 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 37,306 followers.

Early view in Arthritis & Rheumatology #ACR21 The Interleukin-4 Receptor–Associated Kinase Inhibitor PF-06650833 Blocks Inflammation in Preclinical Models of Rheumatic Disease and in Humans Enrolled in a Randomized Clinical Trial https://t.co/c6w3tK…

The IRAK4 kinase inhibitor PF‐06650833 blocks inflammation in preclinical models of rheumatologic disease and in humans enrolled in a randomized clinical trial https://t.co/MMgziylvPC

#ResearchHighlight | IRAK4 inhibitor attenuates inflammation #arthritis #lupus #therapy #rheumatology Read the original research from @ACR_Journals here https://t.co/5s0F3CjSLy Read our #news story here https://t.co/ZCoyZSoo9w

RT @ACR_Journals: Just accepted in Arthritis & Rheumatology: The IRAK4 kinase inhibitor PF-06650833 blocks inflammation in preclinical mod…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.